AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33658762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35743694 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced crystalloid solution (Optilyte®) 20 mL/kg
Number of subjects: 25
Study 35743694 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine 26.500 Da (Geloplasma®) 20 mL/kg
Number of subjects: 25
Study 32628751 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of smoking initiation
Number of subjects: 12
Study 32628751 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 12
Study 32628751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes per day, smoking initiation, smoking cessation, coffee consumption
Number of subjects: 12
Study 35229697 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training in addition to early passive motion protocol
Number of subjects: 22
Study 35229697 — intervention group
Group type: COMPARATOR
Intervention: Early passive motion protocol
Number of subjects: 22
Study 33125516 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat 0.5–15.0 mg solution (first‐in‐human study) or 1.25–10.0 mg immediate release (IR tablets) single dose
Number of subjects: 265
Study 33125516 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat 1.25–10.0 mg IR tablets once daily (QD) or 5.0 mg IR tablets twice daily for 7 consecutive days
Number of subjects: 265
Study 33125516 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat 5.0 mg IR tablets with food
Number of subjects: 265
Study 33125516 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat 15.0 mg (oral solution, fasted)
Number of subjects: 265
Study 33125516 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat ≤ 10.0 mg, IR tablets
Number of subjects: 265
Study 35950339 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Living Triple P–Positive Parenting Program (n = 22)
Number of subjects: 50
Study 35950339 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (n = 28)
Number of subjects: 50
Study 33788855 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline data including DXA obtained Subtotal fat percentage and Subtotal lean mass
Number of subjects: 0
Study 33788855 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithms
Number of subjects: 0
Study 32176711 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Antithrombotic Treatment (OAT)
Number of subjects: 100
Study 32176711 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenprocoumon or Warfarin
Number of subjects: 100
Study 32176711 — intervention group
Group type: EXPERIMENTAL
Intervention: INR Measurement
Number of subjects: 100
Study 32176711 — intervention group
Group type: COMPARATOR
Intervention: Recruitment Stages
Number of subjects: 100
Study 32176711 — intervention group
Group type: COMPARATOR
Intervention: Age Comparison
Number of subjects: 100
Study 36060518 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy (MED)
Number of subjects: 523
Study 36060518 — intervention group
Group type: COMPARATOR
Intervention: CABG plus Medical therapy (CABG + MED)
Number of subjects: 523
Study 34157357 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 0
Study 34157357 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine and Isosorbide Dinitrate (ISDNHYD)
Number of subjects: 0
Study 32333162 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA)
Number of subjects: 739
Study 32333162 — intervention group
Group type: COMPARATOR
Intervention: No Obstructive Sleep Apnea (Control)
Number of subjects: 739
Study 34793868 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 10 mg once daily
Number of subjects: 931
Study 34793868 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 25 mg once daily
Number of subjects: 931
Study 34793868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 931
Study 34930152 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 1233
Study 34930152 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA Covid-19 vaccination (Moderna and Pfizer-BioNTech)
Number of subjects: 1233
Study 34930152 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 1233
Study 36078394 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuna manual therapy + usual care
Number of subjects: 132
Study 36078394 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 132
Study 33612123 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization (IASTM) combined with neuromuscular exercises
Number of subjects: 20
Study 33612123 — intervention group
Group type: COMPARATOR
Intervention: Classical massage combined with the same set of exercises
Number of subjects: 20
Study 32176364 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure postdilatation using noncompliant balloons
Number of subjects: 810
Study 32176364 — intervention group
Group type: COMPARATOR
Intervention: Moderate-pressure dilatation using stent balloons
Number of subjects: 810
Study 35941553 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning and Coping (LC)
Number of subjects: 514
Study 35941553 — intervention group
Group type: COMPARATOR
Intervention: Empowerment, Motivation and Medical Adherence (EMMA)
Number of subjects: 514
Study 32324902 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy (AIT)
Number of subjects: 0
Study 32324902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32393220 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital chest drainage system
Number of subjects: 102
Study 32393220 — intervention group
Group type: COMPARATOR
Intervention: Analogue chest drainage system
Number of subjects: 102
Study 35173020 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal AC block
Number of subjects: 95
Study 35173020 — intervention group
Group type: COMPARATOR
Intervention: Femoral triangle block
Number of subjects: 95
Study 35173020 — intervention group
Group type: COMPARATOR
Intervention: Proximal AC block
Number of subjects: 95
Study 34660225 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal mentoring program (health education, monitoring, text-message reminders)
Number of subjects: 205
Study 34660225 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mentoring program)
Number of subjects: 205
Study 34660225 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal mentoring program
Number of subjects: 205
Study 32516351 — intervention group
Group type: COMPARATOR
Intervention: Secondary or post-secondary education
Number of subjects: 3984
Study 32516351 — intervention group
Group type: COMPARATOR
Intervention: Highest asset quartile (most affluent)
Number of subjects: 3984
Study 32516351 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SES
Number of subjects: 3984
Study 32516351 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher SES
Number of subjects: 3984
Study 35485630 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach back method (4 sessions, each 45 minutes)
Number of subjects: 200
Study 35485630 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study 35485630 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach back method
Number of subjects: 200
Study 35485630 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 33043691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine/Clonidine mixture
Number of subjects: 124
Study 33043691 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 124
Study 35850367 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea treatment
Number of subjects: 0
Study 35850367 — intervention group
Group type: EXPERIMENTAL
Intervention: Tannic acid treatment
Number of subjects: 0
Study 35850367 — intervention group
Group type: COMPARATOR
Intervention: Untreated pellicles
Number of subjects: 0
Study 32221489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental/Incisive Nerve Block (MINB) using 4% Articaine
Number of subjects: 0
Study 32221489 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior Alveolar Nerve Block (IANB) using 4% Articaine
Number of subjects: 0
Study 32221489 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MINB and IANB
Number of subjects: 0
Study 36030106 — intervention group
Group type: EXPERIMENTAL
Intervention: 1PC111 (fixed-dose combination of pitavastatin 2 mg and ezetimibe 10 mg)
Number of subjects: 388
Study 36030106 — intervention group
Group type: COMPARATOR
Intervention: Pitavastatin (2 mg)
Number of subjects: 388
Study 36030106 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe (10 mg)
Number of subjects: 388
Study 36030106 — intervention group
Group type: EXPERIMENTAL
Intervention: 1PC111
Number of subjects: 388
Study 34425869 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant
Number of subjects: 114
Study 34425869 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 114
Study 35760659 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized guides (cutting guides and patient-fitted osteosynthesis plates)
Number of subjects: 30
Study 35760659 — intervention group
Group type: COMPARATOR
Intervention: CAD/CAM surgical splints
Number of subjects: 30
Study 35213214 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Sorafenib
Number of subjects: 2427
Study 34620618 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon autoinjector (GAI) 1 mg
Number of subjects: 161
Study 34620618 — intervention group
Group type: COMPARATOR
Intervention: Glucagon emergency kit (GEK) 1 mg
Number of subjects: 161
Study 35282747 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on social cognitive theory
Number of subjects: 300
Study 35282747 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 35167949 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy (AG)
Number of subjects: 91
Study 35167949 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (PG)
Number of subjects: 91
Study 35167949 — intervention group
Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 91
Study 34344286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy rotation (PTR)
Number of subjects: 17
Study 34344286 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 35459911 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional milk (CON)
Number of subjects: 40
Study 35459911 — intervention group
Group type: EXPERIMENTAL
Intervention: a2 Milk™ (A2M)
Number of subjects: 40
Study 35459911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free conventional milk (LF-CON)
Number of subjects: 40
Study 36191669 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 g portion size
Number of subjects: 44
Study 36191669 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 g portion size
Number of subjects: 44
Study 36191669 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 g portion size
Number of subjects: 44
Study 36191669 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 g portion size
Number of subjects: 44
Study 36191669 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster eating rate
Number of subjects: 44
Study 36191669 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger bite size
Number of subjects: 44
Study 36191669 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher bite count
Number of subjects: 44
Study 36191669 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer meal duration
Number of subjects: 44
Study 36191669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory-specific satiety (SSS)
Number of subjects: 44
Study 34197792 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered interRAI Check-Up Assessment (CUSR)
Number of subjects: 184
Study 34197792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay interviewer-assisted interRAI Check-Up Assessment (CUSR)
Number of subjects: 184
Study 34197792 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported health needs assessment using CUSR
Number of subjects: 184
Study 34197792 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported difficulty in completing the assessment
Number of subjects: 184
Study 34197792 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported health status and phone use
Number of subjects: 184
Study 34197792 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant feedback on CUSR items
Number of subjects: 184
Study 32180369 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 532
Study 35569035 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose combination group (180 μg albuterol and 160 μg budesonide)
Number of subjects: 3132
Study 35569035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose combination group (180 μg albuterol and 80 μg budesonide)
Number of subjects: 3132
Study 35569035 — intervention group
Group type: COMPARATOR
Intervention: Albuterol-alone group (180 μg albuterol)
Number of subjects: 3132
Study 34448709 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) provided to PrEP users (471 participants)
Number of subjects: 939
Study 34448709 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) provided to PrEP users
Number of subjects: 939
Study 34448709 — intervention group
Group type: COMPARATOR
Intervention: Daily PrEP
Number of subjects: 939
Study 32543684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month DAPT (90 mg twice daily)
Number of subjects: 3056
Study 32543684 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor-based 12-month DAPT
Number of subjects: 3056
Study 32543684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month DAPT
Number of subjects: 3056
Study 36296939 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with carrot-derived rhamnogalacturonan-I (cRG-I)
Number of subjects: 0
Study 32682946 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole IV 3.5, 4.5 or 6.0 mg/kg/d for ≥10 days
Number of subjects: 0
Study 32682946 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole PFS at the identical dose for ≤18 days
Number of subjects: 0
Study 32682946 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole IV and PFS
Number of subjects: 0
Study 33017784 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide/50% oxygen
Number of subjects: 48
Study 33017784 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen placebo
Number of subjects: 48
Study 35764793 — intervention group
Group type: EXPERIMENTAL
Intervention: slow yogic breathing
Number of subjects: 18
Study 35764793 — intervention group
Group type: EXPERIMENTAL
Intervention: deep abdominal breathing
Number of subjects: 18
Study 35764793 — intervention group
Group type: EXPERIMENTAL
Intervention: deep diaphragmatic breathing
Number of subjects: 18
Study 35764793 — intervention group
Group type: EXPERIMENTAL
Intervention: deep chest breathing
Number of subjects: 18
Study 35764793 — intervention group
Group type: EXPERIMENTAL
Intervention: three-part breath (deep abdominal, deep diaphragmatic, deep chest breathing)
Number of subjects: 18
Study 35764793 — intervention group
Group type: COMPARATOR
Intervention: spontaneous breathing
Number of subjects: 18
Study 32735752 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, cisplatin or oxaliplatin, and capecitabine (ECC/EOC)
Number of subjects: 781
Study 32735752 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 781
Study 32735752 — intervention group
Group type: EXPERIMENTAL
Intervention: VTE occurrence
Number of subjects: 781
Study 34999830 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective freeze
Number of subjects: 619
Study 33077240 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced needle (20/17 gauge)
Number of subjects: 95
Study 33077240 — intervention group
Group type: COMPARATOR
Intervention: Standard needle (16 gauge)
Number of subjects: 95
Study 34991428 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation
Number of subjects: 30
Study 34991428 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation combined with myofascial release technique
Number of subjects: 30
Study 33755118 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning and Coping Cardiac Rehabilitation (LC-CR)
Number of subjects: 825
Study 33755118 — intervention group
Group type: COMPARATOR
Intervention: Standard Cardiac Rehabilitation (Control)
Number of subjects: 825
Study 33266499 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-reduced anti-inflammatory diet
Number of subjects: 81
Study 36239644 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 340
Study 36239644 — intervention group
Group type: COMPARATOR
Intervention: Best medical care (control)
Number of subjects: 340
Study 33531690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 0
Study 33531690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32700953 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSAAF
Number of subjects: 346
Study 32700953 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 346
Study 36002795 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual scanning exercises along with task specific approach
Number of subjects: 64
Study 36002795 — intervention group
Group type: COMPARATOR
Intervention: Task specific approach alone
Number of subjects: 64
Study 36002795 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of total scores between experimental and control groups
Number of subjects: 64
Study 34686604 — intervention group
Group type: EXPERIMENTAL
Intervention: Language-matching intervention
Number of subjects: 0
Study 32722799 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 570
Study 32722799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 570
Study 32722799 — intervention group
Group type: COMPARATOR
Intervention: SRF presence at baseline
Number of subjects: 570
Study 32722799 — intervention group
Group type: COMPARATOR
Intervention: Baseline fluid volumes
Number of subjects: 570
Study 34918951 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment for 26 weeks
Number of subjects: 37
Study 34918951 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 26 weeks
Number of subjects: 37
Study 34918951 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment for 26 weeks in nonproliferative diabetic retinopathy subgroup
Number of subjects: 37
Study 34918951 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 26 weeks in nonproliferative diabetic retinopathy subgroup
Number of subjects: 37
Study 34918951 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment for 26 weeks in proliferative diabetic retinopathy subgroup
Number of subjects: 37
Study 34918951 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 26 weeks in proliferative diabetic retinopathy subgroup
Number of subjects: 37
Study 32705801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol
Number of subjects: 29
Study 32705801 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 29
Study 33988338 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) with tacrolimus and prednisone (rabbit antithymocyte globulin/EVR)
Number of subjects: 288
Study 33988338 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) with tacrolimus and prednisone (basiliximab/EVR)
Number of subjects: 288
Study 33988338 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate with tacrolimus and prednisone (basiliximab/mycophenolate)
Number of subjects: 288
Study 34105796 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight
Number of subjects: 500000
Study 34105796 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) of birth weight
Number of subjects: 500000
Study 34105796 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation analysis
Number of subjects: 500000
Study 34105796 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable MR analyses
Number of subjects: 500000
Study 34105796 — intervention group
Group type: EXPERIMENTAL
Intervention: Three BMD phenotypes (eBMD, TB-BMD, FN-BMD)
Number of subjects: 500000
Study 32516725 — intervention group
Group type: EXPERIMENTAL
Intervention: True indoor air filtration
Number of subjects: 29
Study 32516725 — intervention group
Group type: COMPARATOR
Intervention: Sham indoor air filtration
Number of subjects: 29
Study 34371826 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program alone (n = 11)
Number of subjects: 46
Study 34371826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-exercise program and nutrition supplement (n = 23)
Number of subjects: 46
Study 34371826 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n = 12)
Number of subjects: 46
Study 32143065 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recall intervention group (Memflex protocol)
Number of subjects: 31
Study 32143065 — intervention group
Group type: COMPARATOR
Intervention: Basic recall control group
Number of subjects: 31
Study 35405087 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy plus bevacizumab
Number of subjects: 160
Study 35405087 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel plus bevacizumab
Number of subjects: 160
Study 32894227 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical culprit lesion locations (CCLL)
Number of subjects: 626
Study 32894227 — intervention group
Group type: COMPARATOR
Intervention: Non-CCLL
Number of subjects: 626
Study 33504408 — intervention group
Group type: EXPERIMENTAL
Intervention: Treprostinil
Number of subjects: 14
Study 33504408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 33504408 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 14
Study 33504408 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exercise
Number of subjects: 14
Study 33504408 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant work rate exercise
Number of subjects: 14